β3-Adrenergic receptor overexpression in cardiomyocytes preconditions mitochondria to withstand ischemia–reperfusion injury
Authors:
Open Access
- 12 August 2024
- journal article
- research article
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 119 (5) , 773-794
Abstract
β3-Adrenergic receptor (β3AR) agonists have been shown to protect against ischemia–reperfusion injury (IRI). Since β3ARs are present both in cardiomyocytes and in endothelial cells, the cellular compartment responsible for this protection has remained unknown. Using transgenic mice constitutively expressing the human β3AR (hβ3AR) in cardiomyocytes or in the endothelium on a genetic background of null endogenous β3AR expression, we show that only cardiomyocyte expression protects against IRI (45 min ischemia followed by reperfusion over 24 h). Infarct size was also limited after ischemia–reperfusion in mice with cardiomyocyte hβ3AR overexpression on top of endogenous β3AR expression. hβ3AR overexpression in these mice reduced IRI-induced cardiac fibrosis and improved long-term left ventricular systolic function. Cardiomyocyte-specific β3AR overexpression resulted in a baseline remodeling of the mitochondrial network, characterized by upregulated mitochondrial biogenesis and a downregulation of mitochondrial quality control (mitophagy), resulting in elevated numbers of small mitochondria with a depressed capacity for the generation of reactive oxygen species but improved capacity for ATP generation. These processes precondition cardiomyocyte mitochondria to be more resistant to IRI. Upon reperfusion, hearts with hβ3AR overexpression display a restoration in the mitochondrial quality control and a rapid activation of antioxidant responses. Strong protection against IRI was also observed in mice infected with an adeno-associated virus (AAV) encoding hβ3AR under a cardiomyocyte-specific promoter. These results confirm the translational potential of increased cardiomyocyte β3AR expression, achieved either naturally through exercise or artificially through gene therapy approaches, to precondition the cardiomyocyte mitochondrial network to withstand future insults.Keywords
Funding Information
- H2020 European Research Council (819775)
This publication has 87 references indexed in Scilit:
- β3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Associated with Heart Failure (SPHERE-HF): A Double Blind, Placebo-Controlled, Randomized Clinical TrialEuropean Journal of Heart Failure, 2022
- Intravenous metoprolol during ongoing STEMI ameliorates markers of ischemic injury: a METOCARD-CNIC trial electrocardiographic studyBasic Research in Cardiology, 2021
- Metoprolol blunts the time-dependent progression of infarct sizeBasic Research in Cardiology, 2020
- Coronary microvascular obstruction: the new frontier in cardioprotectionBasic Research in Cardiology, 2019
- UCP2 protect the heart from myocardial ischemia/reperfusion injury via induction of mitochondrial autophagyJournal of Cellular Biochemistry, 2019
- Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertensionBasic Research in Cardiology, 2016
- Wire Myography to Study Vascular Tone and Vascular Structure of Isolated Mouse Arteries2015
- Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapyBasic Research in Cardiology, 2014
- β3 adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytesBasic Research in Cardiology, 2014
- Tie2-Cre Transgenic Mice: A New Model for Endothelial Cell-Lineage Analysis in VivoDevelopmental Biology, 2001